Stock BIVI BIOVIE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials BioVie Inc.

Equities

BIVI

US09074F2074

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.4848 USD -0.84% Intraday chart for BioVie Inc. -0.35% -61.52%
Mar. 11 BioVie Inc. Announces Pipeline Update and Near-Term Clinical Priorities CI
Mar. 04 Top Midday Decliners MT

Valuation

Fiscal Period: Juni 2020 2021 2022 2023 2024
Capitalization 1 72.79 378.5 36.23 156.4 26.62
Enterprise Value (EV) 1 72.79 378.5 36.23 156.4 26.62
P/E ratio -2.04 x -1.14 x -1.37 x -2.78 x -0.48 x
Yield - - - - -
Capitalization / Revenue - - - - -
EV / Revenue - - - - -
EV / EBITDA - - - - -
EV / FCF - -36,214,295 x -1,907,599 x - -
FCF Yield - -0% -0% - -
Price to Book - - - - -
Nbr of stocks (in thousands) 5,199 22,333 24,984 36,281 54,902
Reference price 2 14.00 16.95 1.450 4.310 0.4848
Announcement Date 8/6/20 8/30/21 9/27/22 8/16/23 -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2020 2021 2022 2023 2024
Net sales 1 - - - - -
EBITDA - - - - -
EBIT 1 -2.693 -138.1 -27.25 -45.08 -48.6
Operating Margin - - - - -
Earnings before Tax (EBT) 1 - -130.2 -26.08 -50.26 -49.4
Net income 1 - -183.8 -26.08 -50.26 -49.4
Net margin - - - - -
EPS 2 -6.850 -14.82 -1.060 -1.550 -1.020
Free Cash Flow - -10.45 -18.99 - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 8/6/20 8/30/21 9/27/22 8/16/23 -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - - -
EBITDA - - - - - - - - - - - -
EBIT 1 - -6.665 -5.749 -9.292 -8.834 -11.49 -13.77 -10.98 - -8.781 -12.55 -13.49
Operating Margin - - - - - - - - - - - -
Earnings before Tax (EBT) 1 - -5.414 -7.041 -8.089 -10.42 -15.69 -15.04 -9.112 - -8.401 -12.88 -13.72
Net income 1 -5.541 -5.414 -7.041 -8.089 -10.42 -15.69 -15.04 -9.112 - -8.401 -12.88 -13.72
Net margin - - - - - - - - - - - -
EPS 2 -0.2300 -0.2200 -0.2800 -0.3300 -0.3800 -0.5000 -0.4300 -0.2300 -0.2900 -0.2200 -0.2500 -0.2600
Dividend per Share - - - - - - - - - - - -
Announcement Date 11/10/21 2/8/22 5/11/22 9/27/22 11/4/22 2/10/23 5/12/23 8/16/23 11/8/23 2/13/24 - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2021 2022 2023 2024
Net Debt - - - -
Net Cash position - - - -
Leverage (Debt/EBITDA) - - - -
Free Cash Flow -10.5 -19 - -
ROE (net income / shareholders' equity) - - - -
ROA (Net income/ Total Assets) - - - -
Assets 1 - - - -
Book Value Per Share - - - -
Cash Flow per Share - - - -
Capex - - - -
Capex / Sales - - - -
Announcement Date 8/30/21 9/27/22 8/16/23 -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.4848
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BIOVIE INC. Stock BioVie Inc.
-61.52% 26.62M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BIVI Stock
  4. Financials BioVie Inc.